VFA
ABEO icon

Virtus Fund Advisers’s Abeona Therapeutics ABEO Stock Holding History

Virtus Fund Advisers’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$346K Buy
+874
New +$361K ﹤0.01% 411

Other funds holding ABEO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Virtus Fund Advisers's ABEO Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Abeona Therapeutics (ABEO) in Q4 2017: 874 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #411 among its holdings.

93 funds tracked by Wall St. Rank hold ABEO as of Q4 2017.

  • Virtus Fund Advisers held 874 shares of Abeona Therapeutics worth $346K as of Q4 2017.
  • Abeona Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Abeona Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #411 holding.
  • 93 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.